Torrecillas S, Perrot E, Gérinière L, Locatelli-Sanchez M, Laffay L, Souquet P-J, Couraud S
Centre de coordination en cancérologie, hospices civils de Lyon, centre hospitalier Lyon Sud, 165, chemin du Grand-Revoyet, 69495 Pierre-Bénite cedex, France; Service de pneumologie aiguë spécialisée et cancérologie thoracique, hospices civils de Lyon, centre hospitalier Lyon Sud, 165, chemin du Grand-Revoyet, 69495 Pierre-Bénite cedex, France.
Service de pneumologie aiguë spécialisée et cancérologie thoracique, hospices civils de Lyon, centre hospitalier Lyon Sud, 165, chemin du Grand-Revoyet, 69495 Pierre-Bénite cedex, France.
Rev Pneumol Clin. 2016 Feb;72(1):25-34. doi: 10.1016/j.pneumo.2015.03.005. Epub 2015 Jul 22.
Oral targeted therapies are a new option for lung cancer treatment. However, patient's belief about these drugs - which may interact with adherence - is poorly known in this setting.
Our study is a pilot prospective unicentric study. Inclusion criteria were: to have been diagnosed with a lung cancer; and to be prescribed with an oral targeted therapy in second line or more. The main objective was to assess patient's specific (SB) and general beliefs (GB) about these drugs according to the Beliefs about Medicines Questionnaire (BMQ). The declared adherence was assessed with the Morisky's test. All included patients underwent a semi-structured interview with a psychologist.
Fifthteen patients were included: 12 underwent erlotinib treatment and 3 a crizotinib treatment. The mean score (±standard deviation) at BMQ was 54/85 (±6) overall; 34/50 (±5) for specific belief and 19/35 (±3) for general belief about drugs. During interview, 47% believed in efficacy of targeted oral therapy; 93% reported concerns about their drug; 80% considered that the information given by the physician about the drug was comprehensive; but 40% still required additional information about it. The mean score at Morisky's test was 3/4 (±2) and 53% reported to have forgotten at least once their antineoplastic drug. No correlation was found between belief and adherence.
Belief about t anti-cancer targeted oral therapy is relatively fair but adherence is moderate in this pilot study. Interview shows the need for additional information about the prescribed drug.
口服靶向治疗是肺癌治疗的一种新选择。然而，在这种情况下，患者对这些药物的看法（这可能与依从性相关）却鲜为人知。
我们的研究是一项前瞻性单中心试点研究。纳入标准为：已被诊断为肺癌；且被处方二线及以上的口服靶向治疗。主要目的是根据药物信念问卷（BMQ）评估患者对这些药物的特定信念（SB）和一般信念（GB）。使用莫利斯基测试评估宣称的依从性。所有纳入患者均接受了心理学家的半结构化访谈。
纳入了15名患者：12名接受厄洛替尼治疗，3名接受克唑替尼治疗。BMQ的平均得分（±标准差）总体为54/85（±6）；关于药物的特定信念平均得分为34/50（±5），一般信念平均得分为19/35（±3）。在访谈中，47%的患者相信口服靶向治疗的疗效；93%的患者表示担心他们的药物；80%的患者认为医生提供的关于药物的信息是全面的；但40%的患者仍需要关于该药物的更多信息。莫利斯基测试的平均得分为3/4（±2），53%的患者报告至少有一次忘记服用抗肿瘤药物。未发现信念与依从性之间存在相关性。
在这项试点研究中，对抗癌口服靶向治疗的信念相对较好，但依从性中等。访谈表明需要关于所开药物的更多信息。
